Business · 27/04/2020Updated: 10/17/2026 · 1 min read
FDA Considers Exclusive Patent License for Seasonal Influenza Vaccine
Summary
The U.S. Food and Drug Administration (FDA) is evaluating a potential exclusive patent license agreement with Sciogen Inc. to develop, produce, and commercialize a seasonal influenza vaccine.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →